Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 in recurrent or metastatic nasopharyngeal carcinoma after ≥2nd-line chemotherapy failure
CTR20180865Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Hengrui Therapeutics. Started Jun 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20180865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180865.